title: Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children.
abstract: The effects of progenitor cell dose on the recovery kinetics of hematopoiesis were assessed in 34 children who underwent marrow-ablative chemotherapy with peripheral blood stem cell (PBSC) autografting. One patient was not engrafted, probably because of a low dose of reinfused cells. In 25 patients whose PBSCs were harvested after intensive chemotherapy without recombinant granulocyte colony-stimulating factor (rG-CSF), we found a significant correlation between the colony-forming unit for granulocyte-macrophage (CFU-GM) infused per kilogram of the patient's body weight and the time to achieve an absolute granulocyte count (AGC) of > 0.5 x 10(9)/L (r = -0.817, p < 0.001) or a platelet count of > 50 x 10(9)/L (r = -0.703, p < 0.001). No association was seen between the number of burst-forming units for erythroid (BFU-E) infused and the speed of hematopoietic recovery. In the other 8 patients with low progenitor yields (< 1 x 10(5) CFU-GM/kg), in vivo induction of PBSC was attempted by administering rG-CSF (250 to 1000 micrograms/m2/day). Seven-day administration of rG-CSF before each leukapheresis increased the committed (CFU-GM: 37.7-fold; BFU-E: 45.6-fold) as well as multipotent (CFU-mix: 6.8-fold) progenitors. These collected cells were cryopreserved and then reinfused. Using a model for simulating hematopoietic recovery kinetics, we suggest that cells induced by rG-CSF could speed the recovery of granulocyte or platelet counts after PBSC autografting.
authors.affiliation: Department of Pediatrics, University of Tokushima, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kawano
authors.forename: Y
authors.initials: Y
authors.lastname: Takaue
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Saito
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: A
authors.initials: A
authors.lastname: Hirao
authors.forename: J
authors.initials: J
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Ninomiya
authors.forename: T
authors.initials: T
authors.lastname: Suzue
authors.forename: T
authors.initials: T
authors.lastname: Koyama
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007937:Leukapheresis; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000601:surgery; D007958:Leukocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D009447:Neuroblastoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010976:Platelet Count; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012175:Retinoblastoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D014182:Transplantation, Autologous
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor